Here, prkcb knockdown in HSPCs leads to reduced survival of PKCα-KR-expressing CLL-like cells, concurrent with reduced expression of the leukemic markers CD5 and CD23. This evidence concerns the gene PRKCB and B-cell chronic lymphocytic leukemia.